Chronic lymphocytic leukemia (CLL) is the most common hematological malignancy in Western countries, affecting adults with a median age of 70 years at diagnosis. 1 In the United States, it accounts for at least 30% of all leukemias, 1 with estimates of 15 340 new cases and 4500 deaths in the year 2007 alone. 2 Although different chemotherapeutic agents are used in the treatment of this indolent lymphoid malignancy, none have been shown to be superior in terms of survival advantage. 3, 4 The most active single agent in CLL is the purine nucleoside analog fludarabine (9-b-D-arabinofuranosyl-2-fluoroadenine, or F-ara-A). Clinical studies of F-ara-A monotherapy in CLL have demonstrated it to be at least as effective as alkylator agent therapies, yielding responses in 63-79% of untreated patients and 32-48% of pretreated patients. [5] [6] [7] [8] A recent Cochrane Database meta-analysis of five randomized controlled trials in patients with previously untreated CLL identified significantly increased overall response (OR) and complete response rates, and longer progression-free survival using single agent purine nucleoside analogs compared with standard alkylating agent-based regimens. 4 Clinical resistance to F-ara-A is an important issue, and is frequently observed. Resistance to F-ara-A may occur by several mechanisms, including reduced drug uptake and intracellular drug accumulation. 9 Patients receiving F-ara-A, especially older patients, 10 are at risk for potentially serious complications, including myelosuppression, [11] [12] [13] [14] increased risk of WHO grades III/IV infections, 4, 13 prolonged immunosuppression, 12, 13, [15] [16] [17] and hemolytic anemia. 4, [18] [19] [20] [21] There is currently no practical assay available to predict which CLL patients are most likely to derive benefit from F-ara-A.
Fludarabine requires protein-mediated transport for cellular entry and cytotoxicity. In humans, these transporters include two members of the equilibrative nucleoside transporter (ENT) family (hENT1/2), and three members of the concentrative nucleoside transporter (CNT) family (hCNT1/2/3). We previously reported that high mRNA levels of human concentrative nucleoside transporter 3 (hCNT3) in pre-F-ara-A treatment CLL samples correlated with clinical resistance to F-ara-A, with a shorter time to progression (TTP; hazard ratio, HR, 4.67; Po0.01) and decreased OR (11 vs 69%, P ¼ 0.002). 22 To further evaluate the importance of hCNT3 as a routine clinical predictive marker, in the present study we explored the value of immunohistochemistry (IHC) for the hCNT3 protein as a marker of F-ara-A resistance in CLL.
Materials and methods

Patient Selection
Patients who received F-ara-A for any clinical indication, from 1 November 1999 to 4 July 2005 at the Cross Cancer Institute (CCI) in Edmonton, AB, Canada, were retrospectively identified through computerized pharmacy records. Those with a pathologically confirmed diagnosis of CLL were included provided that all the following criteria were met: (1) no previous F-ara-A treatment prior to tissue sampling; (2) received F-ara-A as monotherapy; and (3) available tissue (lymph node, spleen, liver, bone marrow) suitable for immunohistochemical assessment. Computerized and manual chart review was performed to obtain key clinical parameters, including age, gender, Rai stage, 23 white blood cell count (WBC), absolute lymphocyte count, lactate dehydrogenase level (LDH), Eastern Cooperative Oncology Group (ECOG) performance status score, 24 line of F-ara-A chemotherapy, clinical treatment response, and hematological treatment response. Full human ethics approval was obtained through the Research Ethics Review Board at the CCI.
Evaluation of Response to Fludarabine
The 1996 National Cancer Institute Working Group (NCI/WG) criteria for CLL 25 were used for evaluating response to F-ara-A therapy. The only exception was the bone marrow biopsy criterion for defining complete remission, because of the retrospective nature of the study.
Complete remission was defined by the presence of all the following being present for 2 or more months: absence of symptoms attributable to CLL, normal findings on physical examination, absolute lymphocyte count o4000 per ml, absolute neutrophil count 41500 per ml, platelet count 4100 000 per ml, and untransfused hemoglobin concentration 411 g per 100 ml.
Partial response was defined by the presence of all the following for 2 or more months: a reduction in previously enlarged nodes, spleen, and liver by at least 50%, and absolute neutrophil count Z1500 per ml, or platelet count Z100 000 per ml, or hemoglobin concentration Z11 g per 100 ml, or 50% improvement over pretherapy reductions in hemoglobin concentration and/or platelet count.
Progressive disease was defined by the presence of one or more of the following: an increase of 50% or more in the size of nodes, spleen, liver, or the appearance of new nodal involvement; an increase of 50% or more in the total lymphocyte count to at least 5000 per ml; transformation to a more aggressive histology such as Richter's syndrome.
A complete OR was defined as both a complete hematological response and a complete clinical response. A partial OR was defined as at least a partial clinical response and at least a partial hematological response, but not a complete OR.
Immunohistochemistry of hCNT3 Protein in Banked CLL Tissue
An immunohistochemical assay to detect hCNT3 in clinical samples of CLL was developed using monoclonal antibodies raised against a synthetic hCNT3 peptide (conjugated to keyhole limpet hemocyanin) that corresponded to amino-acid residues 45-69 of the predicted intracellular loop near the N terminus of the protein. The origin and validation of these monoclonal anti-hCNT3 antibodies, named TL3360, are described elsewhere. 26 Goat anti-mouse antibodies and horseradish peroxidase-labeled dextran polymer (DAKO EnVision þ ) were from DAKO Corporation (Carpinteria, CA, USA). All other reagents were of analytical grade and commercially available.
Formalin-fixed paraffin-embedded blocks of pre-F-ara-A treatment archival tissue were obtained from the CCI. Tissue sections of 4-6 mm thickness were dried in an oven at 591C for 2 h. Sections were rehydrated through three changes of xylene, graded ethanol from 100 to 50%, and then water (10 min per change). Slides were microwaved in a rapid microwave histoprocessor (RHS Milestone, Bergamo, Italy) at a controlled final temperature of 1001C for 10 min in DAKO TRIS buffer (pH 9.9), cooled for 6 min, and washed in running cold tap water. Slides were incubated in 3% H 2 O 2 in methanol for 10 min, 2) and immersed in PBS for 5 min, incubated with Envision (DAKO EnVision þ ) goat anti-mouse dextran conjugate for 30 min, washed in PBS for 5 min, incubated with diaminobenzidene solution, rinsed, counter-stained with hematoxylin, dehydrated through graded alcohols and xylene, and coverslipped. Negative controls were provided by either omitting the TL3360 primary antibodies, by using antibody preparations from which anti-hCNT3 antibodies had been removed by incubation with an excess of anti-hCNT3 peptide, or by substitution of primary antibodies with anti-CD38 monoclonal antibodies. Positive controls were provided by sections of pancreas, a tissue known to express high levels of hCNT3 message 27 and shown to have readily detectible membrane hCNT3 staining by IHC. Quantitative scoring using light microscopy was performed by a hematopathologist (RL) blinded to clinical characteristics and outcomes. Immunohistochemical scoring of hCNT3 protein was assigned a score from 0 to 3 based on staining intensity with homogeneous staining in greater than 50% of the cell population: no staining ¼ 0; weakly positive ¼ 1; moderately positive ¼ 2; and strongly positive ¼ 3.
Primary and Secondary Outcomes
Time to progression, which was calculated from the initiation date of F-ara-A therapy until the date of disease progression, was chosen as the primary end point of this study because it could be determined more reliably than the objective response rate. For those patients surviving without disease progression, TTP was censored at the time of last follow-up. Overall survival (OS) and OR rates were chosen as secondary outcomes.
Univariate and multivariate analyses for TTP and OS were performed using standard statistical techniques, including the Kaplan-Meier method, logrank test, and Cox proportional hazards model. Statistical significance was set at a P-value o0.1 at the univariate level, and a P-value o0.05 at the multivariate level. The w 2 -method was used to analyze OR rates. All statistical analyses were performed using SAS version 9.1.3 software (SAS Institute Inc., Cary, NC, USA).
Results
Baseline Patient Characteristics and Treatment Response
In total, 374 patients received F-ara-A at the CCI for any clinical indication from 1 November 1999 to 4 July 2005. Of those, 51 patients with complete clinical data and who received F-ara-A as treatment for CLL were identified. Of those, 9 patients had either only post-F-ara-A treatment tissue available or unavailable tissue and were therefore excluded from the study. Of the remaining 42 cases, 6 patients received F-ara-A as combination therapy (F-ara-A/ cyclophosphamide, or F-ara-A/cyclophosphamide/ rituximab) rather than as monotherapy and were therefore excluded. Ultimately, 36 patients with CLL who received F-ara-A monotherapy, with suitable pre-F-ara-A treatment tissue available, were included in our study.
Baseline patient characteristics at times of CLL diagnosis and F-ara-A initiation are summarized in Table 1 . Performance status at time of F-ara-A initiation, as measured by the ECOG score, consisted of two patients with score 0, 26 with score 1, seven with score 2, and one with score 3 or 4. The median number of F-ara-A cycles received was 3 (range, 1-8). Eight patients (22%) received six or more cycles. In total, 19 patients received F-ara-A by the intravenous route, 16 by the oral route, and one by Complete hematological responses were observed in seven patients (19%), partial hematological responses in 15 patients (42%), and no hematological responses in 14 patients (39%). Complete clinical responses were observed in 11 patients (31%), partial clinical responses in 13 patients (36%), and no clinical responses in 12 patients (33%). Complete ORs to F-ara-A monotherapy were observed in 6 patients (17%), partial ORs in 14 patients (39%), and no responses in 16 patients (44%).
Quantitative IHC Scoring of hCNT3 Protein
Immunohistochemical staining of hCNT3 protein in pre-F-ara-A treatment samples was quantitatively scored on a 0-3 scale as described earlier. Of the 36 cases, 5 had a score of 0, 12 had a score of 1, 18 had a score of 2, and 1 had a score of 3. Representative photomicrographs are illustrated in Figure 1 .
Relationships between hCNT3 IHC Score and Clinical Outcomes
The CLL population was dichotomized by quantitative hCNT3 staining (scores 0 and 1 vs 2 and 3). The relationship between the dichotomized groups and TTP is shown in Figure 2 . Subjects with high hCNT3 IHC scores (scores 2 and 3) had a significantly shorter TTP with F-ara-A treatment compared to those with low hCNT3 IHC scores (scores 0 and 1), with a median TTP of 4.7 vs 11.2 months, respectively, and a HR of 3.16 (95% CI ¼ 1.39-7.17, Table 2 , were 42% in subjects with high hCNT3 IHC scores (scores 2 and 3), compared with 71% in those with low hCNT3 IHC scores (scores 0 and 1), with w 2 ¼ 2.95 and P ¼ 0.08. OS (not shown) did not differ significantly between the dichotomized groups (P ¼ 0.15).
Discussion
Chronic lymphocytic leukemia is a common, indolent lymphoid malignancy for which no curative treatment currently exists. In the absence of significant patient symptoms, signs, or laboratory abnormalities, many patients are placed on a 'waitand-watch' policy given that standard chemotherapy has not yet been shown to confer a survival advantage. 4 Although several independent prognostic factors, 28 including CD-38, 29 ZAP-70, 30,31 b-2 microglobulin, 32 chromosomal abnormalities, 29 including deletions of 17p or 11q as detected by FISH, and immunoglobulin Vh genes 29 have been identified to discriminate CLL patient populations between favorable and less favorable prognostic groups, the majority of chemotherapeutic decisions are still based upon prognostic groups defined by the Binet et al 33 or Rai 23 staging systems, rather than a validated predictive assay. 34, 35 A recent study found that patients with high-risk cytogenic features such as deletions of 17p or 11q were associated with reduced progression-free survival, and whom should be considered for non-F-ara-A-based therapies. 36 Fludarabine is a nucleoside analog commonly used in the clinical setting as palliative monotherapy for CLL, but it is not an innocuous drug and has potential serious adverse effects, including myelosuppression and prolonged immunosuppression. To date, there are no readily available predictive assays to identify the patient population most likely to benefit from F-ara-A treatment. Although an assay employing ex vivo differential staining cytotoxicity 37 has been used to identify F-ara-A-resistant CLL patient populations, [38] [39] [40] this assay is not widely utilized due to its requirement for purification of CLL cells and 48-h F-ara-A exposures. As we previously reported that high mRNA levels of hCNT3 in pre-F-ara-A treatment CLL samples correlated with clinical resistance to F-ara-A, we undertook this study to further evaluate the importance of IHC for the hCNT3 protein as a routinely applicable clinical predictive marker.
Our results showed a strong and independent relationship between IHC staining of the hCNT3 protein and clinical resistance to F-ara-A therapy in CLL. With the CLL population dichotomized by quantitative hCNT3 staining, there was a significantly shorter TTP in subjects with high hCNT3 IHC scores, with a median TTP of 4.7 months vs a median TTP of 11.2 months in subjects with low hCNT3 IHC scores. Age, WBC count, lymphocyte count, LDH value, and ECOG performance status score were not statistically significant variables at the univariate level. On multivariate analysis incorporating Rai stage and line of F-ara-A treatment, hCNT3 IHC score was the only clinicopathological factor independently associated with TTP, a clinically relevant outcome, with a HR of 3.12 and P-value of 0.01. These results are consistent in magnitude and direction with our previous report. 22 In terms of OR rates, there was a trend toward lower On the basis of these findings, we therefore infer that hCNT3 protein has a direct mechanistic role in cellular resistance to F-ara-A, although the underlying mechanisms are not yet fully understood. Although F-ara-A resistance mechanisms may include reduced drug uptake and intracellular drug accumulation, 9 paradoxically we found that it was high, rather than low, hCNT3 IHC staining that correlated with shorter TTP and clinical resistance. Possible mechanisms include: (1) the regulated coordination of the hCNT3 gene with other genes that indirectly mediate F-ara-A resistance; (2) high hCNT3 expression is a biological marker of a distinct CLL subgroup with intrinsic F-ara-A resistance; and (3) hCNT3 protein localization to intracellular organelles such as the mitochondria may directly modulate F-ara-A toxicity by augmenting physiologic nucleoside uptake.
Although our results show promise that IHC for the hCNT3 protein may be of value as a practical assay to predict which CLL patients are most likely to derive benefit from F-ara-A therapy, our study has some limitations. These include the retrospective nature of the study, relatively small numbers of patients, prior treatment with chlorambucil that might modulate hCNT3 protein abundance and localization, the analysis of heterogeneous tissues, as well as potential intra-and interobserver variabilities in IHC quantitative scoring. In addition, with the exclusion of patients who received F-ara-A as part of combination therapy, it becomes difficult to predict whether our results can be extrapolated to this different population, especially as F-ara-Abased combination therapy becomes more widely used in younger patients and as part of clinical trials. Although the route of F-ara-A administration varied between intravenous and oral, the median dose was similar (710 vs 715 mg, respectively) however, and previous studies have established similar clinical efficacy between the two routes. 41, 42 Our study demonstrates the potential value of adding IHC for the hCNT3 protein to the routine diagnostic IHC evaluation of CLL as a predictive marker in the setting of F-ara-A monotherapy. Larger, multicenter prospective studies are warranted to further validate these observations, including assessment of intra-and interobserver variabilities associated with IHC evaluation. It would also be of great interest to include studies of established prognostic markers, such as ZAP-70 and immunoglobulin Vh mutation status, for correlation with hCNT3. If confirmed, high hCNT3 expression detected by IHC may identify F-ara-A-resistant patients who should pursue non-F-ara-A therapies, thereby avoiding F-ara-A-related toxicities, and would lend further support to attempts to modulate hCNT3 activity to circumvent F-ara-A resistance.
